bmiMD publicly positions itself as a GLP-1 telehealth brand for which we have not independently verified public details; confirm bmiMD lists a licensed prescriber, a named dispensing pharmacy, and whether its product is compounded or FDA-approved before engaging. The details below explain what to verify on its own site, because we have not independently confirmed bmiMD's current pricing, pharmacy, or state availability.
We have not independently verified bmiMD’s pricing. We do not publish estimated or invented prices. When we confirm figures on bmiMD’s own site, this page will show them with a date and a primary-source tag, exactly as our verified provider pages do.
• How bmiMD publicly positions itself (not independently verified): a GLP-1 telehealth brand for which we have not independently verified public details; confirm bmiMD lists a licensed prescriber, a named dispensing pharmacy, and whether its product is compounded or FDA-approved before engaging.
• Verified by us: nothing yet for bmiMD this cycle — pricing, pharmacy, and state availability are unconfirmed.
• Not publicly disclosed / to confirm on its site: the specific compounding pharmacy or 503B facility, whether a product is compounded (not FDA-approved) or FDA-approved, dose-based pricing, membership/shipping/consult fees, cancellation and refund terms, and exact state availability.
• Which specific pharmacy (503A) or outsourcing facility (503B) fills the prescription, and is it named?
• Is the product compounded (not FDA-approved) or the FDA-approved branded drug?
• What is the documented clinical basis for compounding rather than the approved product?
• What is the total monthly cost at my maintenance dose, including all fees?
• Is the prescribing provider licensed for patients in my state, and is shipping refrigerated?
See the full pharmacy transparency checklist and how disclosed providers compare.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
We have not verified which states bmiMD serves. Availability may vary by state and prescribing basis; confirm on its site and check that the prescriber and dispensing pharmacy are licensed for your state. See state notes.
Confirm on bmiMD’s own site. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro; FDA-approved products are reviewed for safety, effectiveness, and quality. We have not independently verified which bmiMD offers.
We have not independently verified bmiMD’s pricing and do not publish estimates. Check its site for the price at your maintenance dose, including any membership, shipping, or consult fees, and compare total cost — see total monthly cost.
We can’t vouch for any provider we haven’t verified. Confirm the prescriber’s license, the named dispensing pharmacy, and whether the product is FDA-approved or compounded. Use our red-flags guide and transparency checklist.
Status. Transparency-first profile, published 2026-06-25. Pricing/pharmacy/state data for bmiMD not yet independently verified; no referral relationship.